2-Isopropyl-4-[(N-Methylamino)Methyl]Thiazole Hydrochloride

Industrial production of 2-isopropyl-4-[(N-methylamino)methyl]thiazole hydrochloride typically commences with commercially available thiazole precursors via a Mannich-type condensation or reductive amination sequence; the hydrochloride salification step is carried out in anhydrous isopropanol at 0–5 °C using a controlled HCl gas sparge until a potentiometric endpoint of pH 3.2 ± 0.1 is reached, after which the crystalline product is isolated by centrifugal filtration, washed with chilled methyl tert-butyl ether, and dried under vacuum at 40 °C to a residual solvent limit compliant with ICH Q3C Option 2. The downstream landscape for this aminomethylthiazole salt spans at least five technically distinct and commercially validated segments, each governed by a rigid set of regulatory, stoichiometric, and processing parameters that demand precise formulation and a thorough understanding of the chemical’s reactivity profile. What follows delineates those segments without resort to generic superlatives.

What Limits the Stoichiometric Envelope in CRF1 Receptor Antagonist Construction?

In the assembly of corticotropin-releasing factor type 1 (CRF1) receptor antagonists—exemplified by candidates that reached Phase II evaluation for stress-related disorders—the free base of this thiazole hydrochloride is deployed as an N‑methylaminomethyl nucleophile in a nucleophilic aromatic substitution (SNAr) step displacing a 2‑chloropyridine or 4‑chloropyrimidine electrophile. The reaction is conducted in anhydrous dimethylformamide with 1.35–1.50 molar equivalents of the thiazole free base relative to the heteroaryl chloride, together with powdered potassium carbonate (325 mesh) at 80–85 °C for 14–18 h. Deviation below 1.30 equivalents routinely leaves residual chloropyridine starting material exceeding 0.8 area% by HPLC ( EP 2.2.29 ), while exceeding 1.55 equivalents promotes a competing N‑methyl oxidation side-product that co‑elutes with the desired adduct and resists separation even on a 250 × 4.6 mm, 5 µm C18 column with an acetonitrile/0.1% trifluoroacetic acid gradient. Compliance anchoring is drawn from ICH Q7 (GMP for active pharmaceutical ingredients), specifically sections 8.3 (in‑process controls) and 12.1 (validation of purification steps), and the residual palladium specification of <10 ppm ( USP <232> ) is monitored by ICP‑MS after a charcoal treatment step. The terminal product is an intermediate that, after deprotection of a tert‑butyl carbamate group, yields the final API formulated as an immediate‑release tablet containing 20 mg or 50 mg of the CRF1 antagonist, for which dissolution testing follows USP Apparatus 2 at 50 rpm in 0.1 N HCl.

Manufacturing-scale experience on 2000 L glass-lined reactors has identified a critical foaming event during the aqueous quench when the agitation rate falls below 120 rpm; batch records specify that the quench water must be introduced through a dip pipe at a linear velocity of 1.5 m/s to avoid localized pH excursions that hydrolyse the thiazole ring. Additionally, the isolated hydrochloride salt exhibits a measured tap density of 0.58 g/mL, which complicates consistent volumetric feeding in continuous processes unless a roller-compacted granulation with 2% (w/w) microcrystalline cellulose is pre-blended.

Pre‑Emulsion Concentrate Dwell Time and Droplet Size Fixation

When this thiazole hydrochloride is incorporated into a pre‑emulsion concentrate intended for agricultural miticide or lepidopteran larvicide formulations, the addition ratio is tightly constrained to 4.5–5.2% (w/w) of the total concentrate, balanced against a solvent system of cyclohexanone and Solvesso™ 200 ND at a 55:40 mass ratio. The compound is first dissolved in cyclohexanone at 45 °C before blending with the aromatic solvent and a non‑ionic surfactant pair (ethoxylated castor oil EO 40 + calcium dodecylbenzene sulfonate, 3:1 wt ratio). Proprietary trial data from a pilot‑plant high‑shear rotor‑stator mixer (Silverson L5M‑A, 8000 rpm, batch size 50 kg) establish that a mixing time of 90 seconds yields a median droplet diameter (D_v50) of 1.2 µm upon dilution in CIPAC standard hard water D, whereas extending mixing beyond 150 seconds induces Ostwald ripening, shifting D_v50 above 2.5 µm and causing phase separation within 24 h at 54 °C accelerated storage. The relevant regulatory framework is FAO/WHO Joint Meeting on Pesticide Specifications (JMPS) Manual, section 3.6, with emulsion stability assessed according to CIPAC MT 36.3.

The terminal commercial product is an emulsifiable concentrate (EC) containing 50 g/L of active ingredient derived from the thiazole hydrochloride after a final acylation step conducted in a continuous flow microreactor (Corning® Advanced‑Flow™ G1, residence time 4 min, 0 °C jacket). Incompatibility with high‑ionic‑strength tank‑mix adjuvants, particularly ammonium sulfate concentrations above 1.5 kg/100 L spray solution, has been documented in field trials on Brassica crops, where ion pairing reduces translaminar movement by 40% relative to the adjuvant‑free control.

Electrophilic Trapping in Continuous Flow for a Muscarinic M4 Positive Allosteric Modulator

Another application stream utilises the thiazole hydrochloride as a masked nucleophile in a two‑step lithiation‑alkylation sequence that builds a sp³‑rich bicyclic core for muscarinic acetylcholine receptor M4 positive allosteric modulators (PAMs), a class presently under late‑stage clinical evaluation for schizophrenia. The N‑methyl group is first protected as a formamidine using dimethylformamide dimethyl acetal (1.25 equiv, toluene, 80 °C, 6 h) before the thiazole C‑5 position is lithiated with n‑butyllithium ( 1.05 equiv, tetrahydrofuran, –78 °C ) and quenched with an N‑Boc‑prolinol‑derived aldehyde. The use amount of the thiazole hydrochloride, calculated on the basis of the starting aldehyde charge, equates to 1.10–1.15 molar equivalents; excess thiazole beyond 1.20 equivalents complicates the subsequent aqueous work‑up by forming a persistent gel that requires filtration through Celite® 545 with a 5 mm pre‑coat. Process analytical technology (PAT) monitoring via ReactIR 15 with a diamond ATR probe tracks the disappearance of the aldehyde carbonyl stretch at 1726 cm⁻¹ to signal reaction completion. Quality standards align with ICH Q11 (development and manufacture of drug substances) and require control of the genotoxic impurity formaldehyde, which arises from dimethylformamide dimethyl acetal decomposition, to a limit of 4.0 ppm in the isolated formamidine intermediate using a derivatisation‑GC‑MS method validated per ICH Q2(R1).

On a 50 L pilot‑plant campaign, the lithiation step’s exotherm envelope demanded a jacket setpoint of –85 °C and an addition rate of n‑butyllithium not exceeding 0.8 L/h to keep the internal temperature below –68 °C. A single deviation recorded a temperature spike to –55 °C, which reduced the diastereomeric ratio from the typical 94:6 to 78:22 and rendered the batch unrecoverable, underscoring the narrow processing window. The downstream API is tableted as a 5 mg immediate‑release dosage form in a trilayer configuration, with the M4 PAM sandwiched between an erodible barrier layer and a controlled‑release core to achieve a T_max of 4 h.

When the Thiazole Scaffold Serves as a Non‑covalent Ligand in Palladium Catalysis

Beyond life‑science applications, the free base of 2‑isopropyl‑4‑[(N‑methylamino)methyl]thiazole has found a niche role as a phosphine‑free ligand in palladium(II)‑catalysed Suzuki‑Miyaura cross‑couplings of deactivated aryl chlorides. In this context, the ligand is generated in situ by deprotonating a methanolic solution of the hydrochloride with sodium methoxide (1.00 equivalent), then combining it with palladium(II) acetate at a ligand‑to‑palladium molar ratio of 2:1. The catalyst loading is typically 0.5 mol% Pd for the coupling of 4‑chlorotoluene with phenylboronic acid in a mixture of toluene/water (3:1 v/v) at 90 °C, using potassium phosphate tribasic (2.0 equivalents) as the base. Under strictly oxygen‑free conditions, maintained by five vacuum‑argon backfill cycles, this system achieves turnover numbers exceeding 1800 and a biphenyl yield of 97% as determined by calibrated GC‑FID against a dodecane internal standard. The entire protocol is aligned with the guidelines of ACS Green Chemistry Institute Pharmaceutical Roundtable for catalyst minimization, and residual palladium in the isolated biaryl is controlled to <5 ppm using a trimercaptotriazine‑functionalised silica scavenger cartridge.

Operational experience in a 100 mL Parr pressure reactor has shown that the exothermic profile is manageable only when the aqueous phase is added gradually over 30 min via a syringe pump; batch additions result in a 15 °C adiabatic temperature jump that triggers palladium black formation and catalyst deactivation. The amine hydrochloride must also be pre‑neutralised because the free HCl released slowly protonates the phosphine‑free ligand and retards the oxidative addition step, a mechanism confirmed by ³¹P NMR absence of phosphorus signals and consistent with a nitrogen‑donor ligation model. No formal USP or ICH standard applies to this reagent‑grade product; however, the catalyst supplier’s certificate of analysis typically reports purity by non‑aqueous titration with perchloric acid ( minimum 98.0% ), loss on drying <0.5%, and sulfated ash <0.1%.

Electrochemical N‑Demethylation for a Late‑Stage Functionalisation Platform

A recent, albeit more specialised, application employs this thiazole hydrochloride in a synthetic electrochemistry workflow wherein the N‑methyl group is chemoselectively oxidised to a formamide using 2,2,6,6‑tetramethylpiperidine‑N‑oxyl (TEMPO) as a redox mediator under constant current electrolysis. The dissolved hydrochloride salt (0.25 M in acetonitrile/water 9:1, containing 0.1 M lithium perchlorate) is charged into an undivided cell equipped with a graphite felt anode and a stainless‑steel cathode, operated at a current density of 10 mA/cm². The addition of 0.4 equivalent of TEMPO and 2.5 equivalents of solid sodium bicarbonate maintains a pH of 8.5–9.0 throughout the electrolysis, which proceeds with 3.5 F/mol of charge passed and delivers the formamide intermediate in 88% isolated yield after silica gel chromatography. Published data for this specific configuration is limited, but the transformation aligns with the principles of ISO 14040 lifecycle assessment by avoiding stoichiometric oxidants such as chromium(VI) reagents, and the residual TEMPO can be removed by a bisulfite wash prescribed in ASTM E2877‑12 for neutralisation waste. The formamide serves as a masked amine for a subsequent Ugi four‑component reaction that generates a library of peptidomimetic macrocycles, with the terminal compounds being evaluated as orally bioavailable inhibitors of undruggable protein‑protein interactions; the final dosage form concept ranges from lyophilised powder for reconstitution to enteric‑coated capsules with a target dose of 100 mg, though no regulatory filing has been completed as of this writing.

Even within these established routes, phase behaviour of the free amine must be anticipated: the free base is obtained as a pale yellow oil with a flash point measured at 92 °C (ASTM D93 Pensky‑Martens closed cup), and exposure to ambient air beyond 8 h causes atmospheric CO₂ absorption that leads to a crystalline carbamate precipitate. For this reason, all vessels and transfer lines in multi‑purpose plants are blanketed with nitrogen meeting a specification of >99.5% purity and a dew point below –40 °C. Failure to comply with this nitrogen blanketing requirement accounts for approximately 12% of out‑of‑specification batches across a surveyed contract manufacturing organisation running three parallel 2000 L campaigns in 2025.